Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 554 across all filing types
Latest filing 2026-05-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于新增认定核心技术人员的公告
Board/Management Information Classification · 97% confidence The document is a corporate announcement by the board regarding the addition of a new core technical personnel in a senior management role. It outlines changes to the company’s management team and provides biographical details of the appointee. This fits the definition of a Board/Management Information filing (MANG) as it announces changes in senior management.
2026-05-29 Chinese
迈威生物关于公司董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is a public announcement regarding the board of directors’ re-election (nominations of independent and non-independent directors, meeting details, candidate resumes), i.e., a change in the company’s board management. This fits the ‘‘Board/Management Information’’ category.
2026-05-29 Chinese
迈威生物独立董事提名人声明与承诺（秦正余）
Board/Management Information Classification · 88% confidence The document is a formal statement and commitment by the company’s board nominating an independent director candidate, detailing qualifications, independence declarations, and eligibility. It pertains directly to board composition and management slate announcements, fitting under the Board/Management Information category.
2026-05-29 Chinese
迈威生物第二届董事会第三十三次会议决议公告
Board/Management Information Classification · 85% confidence The document is a resolution announcement from the company’s board of directors detailing board meeting decisions on board member nominations, proposals for governance changes, and related items. This is a Board/Management Information filing (MANG).
2026-05-29 Chinese
董事、高级管理人员薪酬管理制度
Governance Information Classification · 85% confidence The document is titled “董事、高级管理人员薪酬管理制度” and contains detailed internal governance rules for director and senior management compensation (principles, structure, committees, processes, adjustments). It is a corporate governance policy/manual, not a financial report or announcement. This fits the ‘Governance Information’ category (CGR).
2026-05-29 Chinese
迈威生物关于召开2026年第三次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a detailed notice convening an extraordinary shareholders’ meeting with agenda items, voting methods, proxy form and attachments. It is not the results of votes, nor a financial report, but rather materials sent to shareholders to inform them of meeting logistics and solicit voting. This matches a Proxy Solicitation & Information Statement.
2026-05-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.